Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: An open-label, multicenter, phase I/II trial

Onkologie

Volumn 34, Issue 3, 2011, Pages 101-108

  Ströhlein, Michael A ^a   Lordick, Florian ^b   Rüttinger, Dominik ^c   Grützner, Klaus Uwe ^a   Schemanski, Oliver C ^a   Jäger, Michael ^d   Lindhofer, Horst ^e   Hennig, Michael ^f   Jauch, Karl Walter ^c   Peschel, Christian ^g   Heiss, Markus M ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d TRION Research GmbH   (Germany)

^e TRION Pharma GmbH   (Germany)

^f Fresenius Biotech   (Germany)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antibody, trifunctional; Catumaxomab; Epithelial cell adhesion molecule (EpCAM); Immunotherapy; Peritoneal carcinomatosis

Indexed keywords

CATUMAXOMAB; DEXAMETHASONE; EPITHELIAL CELL ADHESION MOLECULE;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; BREATHING RATE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COLON CANCER; CONSTIPATION; DEHYDRATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EXFOLIATIVE DERMATITIS; FEMALE; FEVER; FLUSHING; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HOT FLUSH; HUMAN; HYPOTENSION; INFECTION; LIVER FUNCTION TEST; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PAIN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RIGOR; SIDE EFFECT; SKIN TOXICITY; STOMACH CANCER; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TACHYCARDIA; TREATMENT RESPONSE; URTICARIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; FEMALE; GERMANY; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 79952257330     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000324667     Document Type: Article

References (25)

1. Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC: Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989;63:364-367. (Pubitemid 19035034)
2. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, Meyer J, Meyer HJ, Buente H: Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989;7:1310-1317. (Pubitemid 19220134)
3. Ajani JA, Ota DM, Jessup JM, Ames FC, McBride C, Boddie A, Levin B, Jackson DE, Roh M, Hohn D: Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer 1991;68:1501-1506.
4. Jayne D.G., Fook S, Loi C, Seow-Choen F: Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002;89:1545-1550. (Pubitemid 35404323)
5. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, François Y, Vignal J, Gilly FN: Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:358-363. (Pubitemid 30051820)
6. Sugarbaker PH, Chang D: Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999;6:727- 731. (Pubitemid 30013648)
7. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737-3743. (Pubitemid 46606227)
8. Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H: Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999;163:1246-1252. (Pubitemid 29352740)
9. Zeidler R, Mysliwietz J, Csánady M, Walz A, Ziegler I, Schmitt B, Wollenberg B, Lindhofer H: The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000;83:261-266. (Pubitemid 30411727)
10. Riesenberg R, Buchner A, Pohla H, Lindhofer H: Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM × alpha CD3). J Histochem Cytochem 2001;49:911-917. (Pubitemid 32565984)
11. Ruf P, Lindhofer H: Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001;98:2526-2534.
12. Heiss MM, Ströhlein MA, Jäger M, Kimmig R, Burges A, Schoberth A, Jauch KW, Schildberg FW, Lindhofer H: Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 2005;117:435-443.
13. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons SL: The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer 2010;127:2209-2221.
14. Seimetz D, Lindhofer H, Bokemeyer C: Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 2010;36:458-467.
15. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA: Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006;94:128-135. (Pubitemid 43088552)
16. Parsons SL, Lang MW, Steele RJ: Malignant ascites: a 2-year review from a teaching hospital. Eur J Surg Oncol 1996;22:237-239. (Pubitemid 26229671)
17. Burges A, Wimberger P, Kümper C, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, Lahr A, Schulze E, Jäger M, Ströhlein MA, Heiss MM, Gottwald T, Lindhofer H, Kimmig R: Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM × anti-CD3 antibody: a phase I/II study. Clin Cancer Res 2007;13:3899-3905. (Pubitemid 47037597)
18. Gilly FN, Carry PY, Sayag AC, Brachet A, Panteix G, Salle B, Bienvenu J, Burgard G, Guibert B, Banssillon V, Braillon G: Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology 1994;41:124- 129. (Pubitemid 24140784)
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
20. Lewis LD, Cole BF, Wallace PK, Fisher JL, Waugh M, Guyre PM, Fanger MW, Curnow RT, Kaufman PA, Ernstoff MS: Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu. J Immunol Methods 2001;248:149-165. (Pubitemid 32167032)
21. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A: Cytokine-release syndrome in patientswith B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999;94:2217-2224. (Pubitemid 29467667)
22. Prandota J: Important role of proinflammatory cytokines/ other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology. Am J Ther 2005;12:254-261. (Pubitemid 40825131)
23. Marmé A, Strauss G, Bastert G, Grischke EM, Moldenhauer G: Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma. Int J Cancer 2002;101:183-189. (Pubitemid 34970911)
24. DeNardo GL, Bradt BM, Mirick GR, DeNardo SJ: Human antiglobulin response to foreign antibodies: therapeutic benefit? Cancer Immunol Immunother 2003;52:309-316. (Pubitemid 36581907)
25. Ott MG, Lindhofer H, Linke RG, Hennig M, Martinius H, Klein A, Seimetz D: The trifunctional antibody catumaxomab: Correlation between immunological response and clinical outcome - new analysis of a pivotal phase II/III study. J Clin Oncol 2010;28(suppl 15):abstr 2551.